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Abstract
Background: Interactions between cancer cells and stroma are critical for growth and invasiveness of
epithelial tumors. The biochemical mechanisms behind tumor-stromal interactions leading to increased
invasiveness and metastasis are mostly unknown. The goal of this study was to analyze the direct effects
of staged stroma-derived extracellular matrices on breast cancer cell behavior.
Methods: Early and late three-dimensional matrices were produced by NIH-3T3 and tumor-associated
murine fibroblasts, respectively. After removing fibroblasts, extracted matrices were re-cultured with
breast epithelial cells of assorted characteristics: MCF-10A (non-tumorigenic), MCF-7 (tumorigenic, non-
invasive), and MDA-MB-231 (tumorigenic, invasive). Effects prompted by staged matrices on epithelial cell's
growth, morphology and invasion were determined. Also, matrix-induced velocity, directionality and
relative track orientation of invasive cells were assessed in the presence or absence of inhibitors of
phosphoinositide-3 kinase (PI3K) and/or beta-1 integrin.
Results: We observed that assorted breast epithelial cells reacted differently to two-dimensional vs.
staged, control (early) and tumor-associated (late), three-dimensional matrices. MCF-10A had a
proliferative advantage on two-dimensional substrates while MCF-7 and MDA-MB-231 showed no
difference. MCF-10A and MCF-7 formed morphologically distinguishable aggregates within three-
dimensional matrices, while MDA-MB-231 exhibited increased spindle-shape morphologies and directional
movements within three-dimensional matrices. Furthermore, MDA-MB-231 acquired a pattern of parallel
oriented organization within tumor-associated, but not control matrices. Moreover, tumor-associated
matrices induced PI3K and beta1-integrin dependent Akt/PKB activity in MDA-MB-231 cells. Interestingly,
beta1-integrin (but not PI3K) regulated tumor-associated matrix-induced mesenchymal invasion which,
when inhibited, resulted in a change of invasive strategy rather than impeding invasion altogether.
Conclusion: We propose that both cells and matrices are important to promote effective breast cancer
cell invasion through three-dimensional matrices and that beta1-integrin inhibition is not necessarily
sufficient to block tumor-matrix induced breast cancer cell invasion. Additionally, we believe that
characterizing stroma staging (e.g., early vs. late or tumor-associated) might be beneficial for predicting
matrix-induced cancer cell responses in order to facilitate the selection of therapies.
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Background
Metastasis, as opposed to tumor growth, is the major
cause of cancer mortality, accounting for 90% of deaths in
solid neoplasias [1], such as breast cancer. Furthermore,
the American Cancer Society has identified breast cancer
as the number one neoplasia in women in the United
States [2]. It is well established that both transformed epi-
thelial cells and their associated stromal microenviron-
ment are active contributors to the development of
mammary and other epithelial cancers [3-5], and that
stromal paracrine effects induce epithelial cell tumori-
genic responses [3], such as increased proliferation [4,6]
and metastasis [7-10]. In breast carcinomas, changes in
the stroma include appearance of discontinuities in the
basement membrane surrounding the growing tumor,
immune responses, formation of new vessels, and a
desmoplastic reaction that includes activated fibroblasts
(myofibroblasts) and remodeling of their mesenchymal
extracellular matrix (ECM) [11-15]. In addition, both
direct and indirect interactions between cancer cells and
the mesenchyme are responsible for triggering the activa-
tion of the tumor-associated stroma (e.g., desmoplasia),
creating a permissive environment in support of tumor
development and cell invasion [5,13,16].
Plasticity of tumor-associated stroma consists of both
molecular and topographical changes that result in part
from altered amounts and availability of matrix-modifica-
tion proteins such as proteases [17], which contribute to
variations in organization and pliability (e.g., stiffness) of
the ECM [18,19]. As a result of these types of tumor-
induced stromal modifications, the microenvironment
differentially engages cell-matrix receptors like the
integrins, which in turn alter cell responses such as cancer
cell invasion [20-22]. Moreover, topographical reorgani-
zation of the ECM, such as the presence of parallel ori-
ented patterns of collagen fibers, facilitates local cell
invasion [15]. Regarding types of invasive strategies,
investigators have proposed that single cell invasion could
occur by either epithelial-to-mesenchymal transitioned
movement or by an amoeboid-like strategy, and that col-
lective cell invasion could involve micro- or macro-track
cell formations, all of which depend on microenviron-
mental characteristics [15,23-25]. Interestingly, it has also
been proposed that tumor cells can transition between
these invasive strategies in response to tumor-induced
stromal plasticity [26,27].
Integrins, which are trans-membrane adhesive receptors
that are composed of heterodimeric subunits designated
as alpha and beta, are responsible for perceiving and
responding to changes in both the extracellular microen-
vironment and the inner cell by linking the ECM to the
cytoskeleton [28]. It has been suggested that beta1-
integrins, which represent the largest integrin subfamily,
play a central role in tumor cell responses that include
invasion and metastasis [29-31]. For example, beta-1
integrins, among others, have been implicated in the reg-
ulation of protein Kinase B (PKB) also known as Akt
[32,33], which consecutively plays crucial roles in regulat-
ing breast cancer cell invasion [34-36]. Furthermore, inhi-
bition of beta-1 integrin has been shown to result in a
change of invasive strategy [37,38].
Due to the influence of the mesenchymal microenviron-
ment on cancer invasion [39], much effort has been
invested in developing 3D model systems that effectively
mimic the in vivo microenvironmental settings [40-42].
Since little is known about the direct effects that tumor-
associated mesenchymal ECMs have on breast epithelial
cell responses during tumor invasion, we have developed
an in vivo-like 3D ECM system [43]. In fact, the original
system has recently been modified to allow the use of a
variety of fibroblasts, which produce self-derived 3D
matrices that mimic successive stages of tumor-induced
stroma progression [44,45]. For instance, 3D ECMs
derived from NIH-3T3 fibroblasts resemble matrices
obtained from primary fibroblasts isolated from primed
or pre-disposed tumor-associated stroma, and hence are
regarded as control or early 3D ECMs [44,46]. Similarly,
3D ECMs obtained from primary fibroblasts harvested
from tumor samples resemble late in vivo or activated
(e.g., desmoplastic) stromal matrices, which present
tumor-associated stromal characteristics such as the
above-mentioned topographical parallel-organized pat-
terns of ECM fibers [44,46]. We believe that staged ECMs
can be used as 3D substrates for epithelial cells in order to
study tumor-associated ECM induced responses such as
growth, cell morphology, and cell invasion [46-48]. Con-
sequently, in the first part of this study and as proof of
principle, we tested the direct effects that in vivo-like con-
trol and tumor-associated mesenchymal 3D ECMs have
on immortalized normal (MCF-10A), tumorigenic (estro-
gen receptor modified MCF-7, [49]) and metastatic
(MDA-MB-231) breast epithelial cells. Furthermore, we
investigated the influences imparted by early (control) vs.
late (tumor-associated) staged 3D ECMs on the regulation
of both the morphological features and the invasive strat-
egies of MDA-MB-231 cells through engagement of beta1-
integrin and/or PI3K.
Methods
Cell lines and culture conditions
NIH-3T3 fibroblasts were purchased from the American
Type Culture Collection (ATCC), Manassas, VA and pre-
conditioned (using 10% fetal bovine serum (FBS)) for 3D
matrix production as published [47]. Primary tumor-asso-
ciated fibroblasts were obtained as described [44], and
used for a maximum of 8 passages. Breast epithelial MCF-
10A and MDA-MB-231 cells were purchased from ATCC,BMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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while modified MCF-7 were a gift from Dr. V. Craig Jor-
dan, FCCC Philadelphia, PA [49]. Fibroblasts were main-
tained in high glucose Dulbecco's modified Eagle's
medium (DMEM; Mediatech Inc., Manassas, VA) contain-
ing 10% FBS (Hyclone, South Logan, UT), MCF-10As in
high calcium DMEM with 5% horse serum (Invitrogen,
Carlsbad, CA), while MCF-7 and MDA-MB-231 in RPMI-
1640 (Mediatech, Inc., Manassas, VA) with 10% FBS. In
addition, MCF-7 medium was complemented with 10
mM MEM Non-Essential Amino Acids Solution (NEAA,
Mediatech, Inc., Manassas, VA), and with 10 ug/ml
Bovine Pancreas Insulin from Sigma Aldrich (St. Louis,
MO). All media were complemented with 100 U/ml pen-
icillin, 100 μg/ml streptomycin, and 2 mM L-glutamine.
Cells were cultured at 37°C in a humidified atmosphere
of 5% CO2.
Inhibitors
Functional blocking anti beta1- integrin antibody, mAb13
[50] used at a concentration of 50 μg/ml, was a gift from
Dr. Kenneth Yamada (NIH/NIDCR, Bethesda, MD).
Wortmannin, used at either 10 or 50 nM, and both nega-
tive controls DMSO and purified Rat IgG were purchased
from Sigma Aldrich (St. Louis, MO).
Production of fibroblast-derived 3D matrix
Murine embryonic fibroblasts, NIH-3T3s, were cultured
in high glucose Dulbecco's modified Eagle's medium con-
taining 10% fetal bovine serum for a minimum of 20 pas-
sages before matrix production to overcome their normal
contact growth inhibition [47]. The resultant, pre-condi-
tioned fibroblasts-derived 3D ECMs have been shown to
be reminiscent of both in vivo and in vitro early stromal
ECMs [44] and are characterized, among others, by ran-
dom organization of fibronectin fibers. Therefore, matri-
ces derived from these fibroblasts are referred to in the
manuscript as "early" or "control" matrices. On the other
hand, "tumor-associated matrices" were obtained from
one, out of four different fibroblastic cell lines, isolated
from advanced ("late") two-staged chemical carcinogenic-
induced murine squamous cell carcinomas [44].
As previously published, the resultant "late" matrices are
reminiscent of in vivo desmoplastic ECMs which are char-
acterized, among others, by a parallel patterned matrix
fiber organization [44]. The above-mentioned "control"
and "tumor-associated" fibroblasts were induced to
secrete and organize their own in vivo-like 3D matrices as
described [44,46,47]. Briefly, 250,000 cells/ml were
plated on chemically cross-linked gelatin and supple-
mented every 48 h with 50 μg/ml L-ascorbic acid (Sigma-
Aldrich, St. Louis, MO). After 5–7 days, 3D matrices were
cleared from cellular components by treatment with 0.5%
(v/v) Triton X-100 and 20 mM NH4OH (Sigma Aldrich,
St. Louis, MO). Resultant 3D matrices were stored at 4°C
in PBS containing 100 U/ml penicillin and 100 μg/ml
streptomycin. Every batch of matrices was characterized
for quality control; matrices needed to be thicker than 7
μm while both types of ECMs were required to display the
fiber organization characteristics associated with in vivo
ECMs (as mentioned above).
Cell growth assay
Cell growth was evaluated using Alamar Blue (Invitrogen,
Carlsbad, CA), according to the manufacturer's instruc-
tions. Briefly, cells were plated at a density of 5,000 or
10,000 cells/well in 48- or 24-well plates and incubated
for 24, 48 or 72 h prior to 10% (v/v) Alamar Blue treat-
ment. After 4 h, changes in fluorescence (λ = 535/595)
were measured using a SpectraFluor Plus (Tecan, San Jose,
CA) plate reader. Wells void of cells were used as negative
controls. All experiments were performed a minimum of
three times in triplicates.
Western blot analysis
1 × 105 cells were pre-incubated with inhibitor(s) or con-
trols (see Inhibitors above) in their respective media and
rotated for 15 min at 37°C. Cells were cultured overnight
in the assorted matrices and lysates were prepared as pre-
viously described [45,51]. Proteins were resolved on SDS-
PAGE using Tris-glycine 8–16% gels (Invitrogen,
Carlsbad, CA) and transferred to PVDF membranes (Mill-
ipore, Bedford, MA). Primary antibodies were: anti-
GADPH (1:5000, Chemicon Int, Millipore, Bedford, MA),
anti-E-cadherin (1:2000, Abcam Inc, Cambridge, MA),
anti-vimentin (1:3000, Sigma Aldrich, St. Louis, MO),
anti-Akt (1:2000, BD Bioscience, San Jose, CA), anti-
pAktS473 (1:1000, Cell Signaling, Beverly, MA), anti-FAK
(1:2000, Upstate, Millipore, Bedford, MA), and anti-
pFAKY397 (1:1000, Biosource, Camarillo, CA). Secondary
antibodies were: goat anti-rabbit and anti-mouse conju-
gated to IRDye800 and IRDye680 (1:15,000 LI-COR, Lin-
coln, NE) for infrared scanning.
Cell invasion within fibroblast-derived 3D matrices
Assays were conducted as previously described [48], with
minor modifications. Briefly, 12 well plates containing
assorted 3D matrices were used and 8,000 MDA-MB-231
cells were cultured overnight in the presence or the
absence of inhibitors or respective negative controls (for
details see Inhibitors above). Fresh medium containing
25 mM HEPES buffer was added, and cells were allowed
to incubate for 1 h at 37°C. Using a motorized XYZ stage
(Optical Apparatus Co., Ardmore, PA), five random
acquisition points were pre-determined for each experi-
mental well. Low throughput movies were created where
each pre-set location was photographed every 10 min for
a period of 6 h using an environmentally controlled
Nikon TE-2000U wide field inverted microscope (Optical
Apparatus Co., Ardmore, PA) with a Roper Scientific CoolBMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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Snap HQ camera rendering 5 time-lapse movies per well
for a total of 60 movies per experimental plate. Non-
dividing and non-clustered cells that remained within the
field of view for the entire 6 h period were tracked using
the "tracking objects" function in MetaMorph offline
7.0r4. The software rendered a set of 37 X,Y coordinates
per recorded cell representing the location of the cell at
every 10 minute time segment. These data sets were trans-
ferred to Microsoft Excel spreadsheets that were designed
to automatically determine velocities (microns per hour),
directionality, relative track orientation and trajectory
length for each cell (see details below). All experiments
were performed a minimum of two times in duplicates
rendering no less than 10 movies per condition tested.
Directionality assay
To evaluate the directionality of cells, trajectory angles of
each cell with respect to the X axis were determined at 10
minute intervals. Angle values were obtained using the
"Tracking objects" function of the MetaMorph software.
This measurement rendered an average of 36 directional
angles per cell, from which the mode angle (most com-
mon angle) was identified. Next, individual angles were
rounded to the nearest 5th degree, and compared to the
identified mode angle. The experimental output per cell
was determined as the percentage of angles that were
within 5 degrees from the identified mode.
Relative track orientation assay
The angle between the cell-track and the X-axis was deter-
mined based on X,Y coordinates obtained from Meta-
Morph software, resulting in a single angle per cell-
trajectory. The resultant cell-track angles for each movie
were rounded to the nearest 20th degree in order to iden-
tify a mode (most common) angle per movie. In order to
normalize the data, all modes were arbitrarily set as 0°,
and the original tracks (per-movie) were rotated accord-
ingly. The rotated track angles were rounded (de novo), to
the 10th degree. Movies in which no mode angle could be
calculated were not rotated. In addition, only movies con-
taining more than three cells were included in the study.
Numbers indicating the percentages of cell-track angles
within 20° from the mode (most common) angle per
experimental condition, as well as total counts, were used
to create the corresponding figures and tables presented.
Cell morphology analysis
The assay was conducted as described [46], with minor
modifications. In short, the first image from each time-
lapse series acquired above (see Cell invasion within
fibroblast-derived 3D matrices) was used for this assay.
Cell contours were manually traced by a blinded individ-
ual and recognized by MetaMorph 7.0r4 software using
"automatic threshold light objects" function. The result-
ant objects were then subjected to "integrated morphom-
etry analysis" to obtain "elliptical form factor" (EFF)
measurements. EFF is defined by the ratio of the "length"
(long axis) over "breath" (short axis) of the cell; round
objects present EFF = 1 while EFF > 1 represent spindled
morphologies. All experiments were performed a mini-
mum of two times, in duplicates rendering no less than 10
images (1 per movie) per condition tested.
Statistical analyses
All statistical analyses were performed using the Mann-
Whitney test and calculated by the Instat Statistical Soft-
ware (GraphPad Software, San Diego, CA).
Results
Staged fibroblast-derived 3D ECMs do not impart a 
preferential growth environment to normal or tumorigenic 
breast epithelial cells
To test whether our stromal staged mesenchymal ECMs
induce breast epithelial cell growth, we cultured MCF-
10A, MCF-7 or MDA-MB-231 cells in 2D conditions, con-
trol (resembling early) or tumor-associated (resembling
late) 3D ECMs and quantitatively measured their growth
rates during a period of 3 days. Our measurements
showed that MCF-10A had a small, yet highly significant,
preference to grow on 2D conditions compared to control
3D ECMs (1.1 fold, with P < 0.0001) or tumor-associated
3D ECMs (1.3 fold, P < 0.0001). The differences in growth
rates on the 3D matrices were also highly significant (P <
0.0001). In contrast, tumorigenic MCF-7 and invasive
MDA-MB-231 cells showed no significant differences in
their growth rates under all conditions tested (Figure 1a).
These results suggested that fibroblast-derived 3D ECMs
differentially regulate the growth rates of some, but not
all, epithelial cells.
Effects of staged 3D ECMs in breast epithelial cell 
morphologies
Since different cell morphologies have been associated
with many tumorigenic characteristics [52,53] and with a
variety of invasive strategies [26,27,54], we proceeded to
ask whether staged 3D matrices could differentially influ-
ence breast epithelial cellular morphologies. MCF-10A,
MCF-7 or MDA-MD-231 cells were cultured overnight on
2D, within 3D control, or within tumor-associated 3D
ECMs, and their morphologies were perceptibly assessed
using transmitted light microscopy. While cell morpholo-
gies were similar on 2D cultures, Figure 1b shows that all
cells presented altered morphologies when comparing 2D
vs. 3D substrates. Interestingly, while both MCF-10A and
MCF-7 seemed to aggregate in cell clusters within 3D
microenvironments, their morphologies were very differ-
ent; MCF-10A became spindle-like, while MCF-7 pre-
sented relatively rounded and less spread morphology. In
comparison, tumorigenic and invasive MDA-MB-231
cells, adopted spindled morphology in both staged 3DBMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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MCF-10A, MCF-7 and MDA-MB-231 exhibit different cell behaviors in response to culturing on 2D or in staged 3D ECMs Figure 1
MCF-10A, MCF-7 and MDA-MB-231 exhibit different cell behaviors in response to culturing on 2D or in staged 
3D ECMs. The stated cells were cultured on 2D (2D Ctrl), within 3D control (3D Ctrl), or within tumor-associated 3D 
ECMs (3D TA). a. Growth rates were calculated every 24 h for a period of 72 h. Note that 3D ECMs appear to be growth 
inhibitory only in MCF-10A cells with slower growth rates induced by tumor-associated 3D matrices. b. phase contrast trans-
mitted light micrographs depicting changes in cell morphologies of the various cell lines in response to the 2D and 3D sub-
strates are shown; scale bar represents 75 μm. c. Western blot of lysates obtained from the various cell lines cultured in the 
assorted substrates showing expressions of epithelial marker E-cadherin (E-cad), mesenchymal marker vimentin and loading 
control glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Note that the 3D ECMs did not alter the original epithelial or 
mesenchymal characteristics of the assorted cells.BMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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ECMs, as expected from these invasive mesenchymal-like
cells. Moreover, matrix-induced morphologies of these
epithelial-to-mesenchymal transitioned cells appeared to
be enhanced (more spindled) within tumor-associated
3D ECMs when compared to 3D control (see measure-
ments below). It is important to note that in addition to
the spindled morphology, MDA-MB-231 cells remained
unclustered as opposed to the other two cell lines tested.
The epithelial or mesenchymal nature of MCF-10A and
MCF-7 or MDA-MB-231 [55] and the fact that 3D matrices
do not affect their epithelial vs. mesenchymal characteris-
tics were confirmed by Western blot analyses using epithe-
lial marker E-cadherin and mesenchymal marker
vimentin (Figure 1c).
Staged 3D matrices effectively support single-cell MDA-
MB-231 and clustered-cell MCF-10A invasion
Real time motility (on control 2D), as well as invasive
(within staged fibroblast-derived 3D matrices) 6 h period
assays, were used to observe correlations between invasive
behaviors and substrate-induced morphologies of the
cells used in this study. MCF-10As were observed to be
motile, on 2D control, and invasive, in both staged 3D
ECMs. In addition, although all cells were seeded as indi-
vidual cells, MCF-10As seemed to cluster and invade
through the staged 3D matrices as aggregates or groups
consisting of several cells (Additional file 1; Movie 1). In
comparison to MCF-10A, MCF-7 and MDA-MB-231 were
not very motile under 2D conditions (see Additional files
2 and 3; Movies 2 and 3). However, while both MCF-10A
and MCF-7 cells clustered in 3D matrices, MCF-7 did not
present any invasive characteristics (Additional file 2;
Movie 2). Alternatively, epithelial to mesenchymal transi-
tioned MDA-MB-231 cells presented apparent mesenchy-
mal-like invasive behaviors (e.g., relatively directional cell
movement through 3D matrices, see Additional file 3;
Movie 3 plus measurements below). These results imply
that matrix-induced cell morphologies could be sugges-
tive of breast cancer cell invasive occurrence (compare Fig-
ure 1b with Additional files 1, 2 and 3; Movies 1–3).
Tumor-associated 3D matrix supports sustained Akt/PKB 
activity regulated by both PI3K and beta1-integrin
Since the serine/threonine protein kinase Akt/PKB, has
been associated with both matrix induced cell survival
and invasion [56,57], matrix-induced Akt/PKB activity
levels were tested. For this, MCF-10A, MCF-7 or MDA-
MD-231 were cultured on 2D conditions, or within staged
3D ECMs for a period of 18h. Cells were lysed and levels
of active (pAktS473) and total Akt/PKB (tAkt) protein pop-
ulations were assessed using Western blot analyses (Figure
2a). In control, compared to tumor-associated 3D ECMs,
constitutive Akt/PKB (pAkt S473/tAkt) activity levels in
MCF-10A and MCF-7 were either down regulated or
remained unchanged (O.D = 0.5 and. 0.3 vs. 1.3 and 1.2,
respectively), while these levels were clearly up-regulated
in MDA-MB-231 cells (O.D = 0.8 and 2.8). These results
suggested that tumor-associated 3D matrices, but not 3D
controls, constitutively activated Akt/PKB in MDA-MB-
231 but not in MCF-10A or MCF-7 cells.
Next, tumor-associated 3D matrix induced pathways
responsible for the observed constitutive activity of Akt/
PKB in MDA-MB-231 cells were analyzed. Since Phosph-
oinositide-3 kinase (PI3K) and beta1-integrin pathways
have been associated with increased levels of Akt/PKB
activities [56,58,59], these two Akt/PKB regulators were
selectively and/or collectively inhibited while levels of
Akt/PKB activity, and of beta1-integrin effector, focal
adhesion kinase (FAK), were assessed. Untreated 2D con-
ditions were used for normalization purposes and
assigned a value of one arbitrary unit. Results show that
PI3K inhibitor, Wortmannin, effectively inhibited Akt/
PKB activity, while anti beta1-integrin functional blocking
antibody, mAb13 [50], inhibited both Akt/PKB and FAK
activities induced by the two staged 3D ECMs. A repre-
sentative Western blot with indicated percentages of FAK
and Akt/PKB inhibitions is displayed in Figure 2b. In
addition, Figure 2b shows that both FAK and Akt/PKB
activities were also effectively inhibited when combina-
tion treatments of Wortmannin and mAb13 were used.
Consequently, both Wortmannin and mAb13 were used
to analyze a variety of staged matrix-induced cell
responses such as cell morphology and various aspects of
cell invasion (e.g., velocity, directionality and relative
track orientation) in the second part of this study.
PI3K and beta1-integrin differentially regulate staged 3D 
matrix-induced MDA-MB-231 spindled morphologies
To better understand tumor-associated induced invasive
breast cancer cell responses, the morphological features of
MDA-MB-231 cells in control (early) vs. tumor-associated
(late) 3D ECM under PI3K, and/or beta1-integrin inhibi-
tion were quantified. For this, MDA-MB-231 cells were
plated overnight within staged 3D ECMs in the presence
or absence of Wortmannin and/or mAb13 (DMSO and/or
rat antibody were used as negative controls; see Methods
for details). As expected, results shown in Figure 3 and
quantified in Table 1 confirmed that increased spindled
morphologies, measured as median elliptical form factor
(mEFF), were indeed observed in tumor-associated when
compared to control 3D ECMs (mEFF = 2.2 and 1.7,
respectively) while Table 2 showed that this increase was
statistically significant (P < 0.0001). Moreover, in control
3D matrices, 10 and 50 nM concentrations of PI3K inhib-
itor Wortmannin show mEFF ratios of 1.5 vs. 1.4, which
were statistically lower than mEFF ratios in untreated 3D
control (P = 0.0016 and < 0.0001, respectively), yet not
significantly different from each other (P = 0.1902). InBMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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Tumor-associated 3D matrix induced Akt/PKB activity in MDA-MB-231 is regulated by both PI3K and beta-1 integrin Figure 2
Tumor-associated 3D matrix induced Akt/PKB activity in MDA-MB-231 is regulated by both PI3K and beta-1 
integrin. a. Representative Western blot showing levels of pAktS473 (pAkt), total Akt (tAkt), and Glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH), used as endogenous protein loading control, in lysates from MCF10A, MCF7 and MDA-
MB231 cultured on 2D or within staged 3D ECMs. Specific Akt/PKB activity was calculated as the ratio of the scanned optical 
density (O.D.) of pAktS473/totalAkt (p/tAkt O.D.). The calculated activity ratios were normalized to ratios obtained for each 
cell line cultured on 2D control conditions and were individually assigned as one arbitrary unit. Note that tumor-associated 3D 
matrix induces high specific Akt/PKB activity levels in MDA-MB-231 but not in MCF-10A or MCF-7 cells. b. Lysates from 
MDA-MB-231 cells cultured on 2D or in staged 3D ECMs in the presence and/or absence of 10 and 50 nM Wortmannin 
(Wt10 and Wt50) and/or 50 μg/ml mAb13 (mAb13) were proved by Western immunoblotting using antibodies against 
pFAKY397 (pFAK), total FAK (tFAK), pAKTS473 (pAkt), total Akt (tAKT) and Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). The percentages of inhibition of FAK (%inh FAK) and Akt/PKB (%inh Akt) activities are shown and were calcu-
lated using the corresponding O.D. ratios: pFAKY397/totalFAK and pAktS473/totalAkt. Note that while Wortmannin inhibited 
Akt/PKB activity, mAb13, alone or in combination with Wortmannin, inhibited both FAK and Akt/PKB activities.BMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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contrast, in tumor-associated 3D ECMs, low concentra-
tions of Wortmannin appeared to have no effect (mEFF =
2.3 with P = 0.5975) while higher concentrations were
needed to attain significant inhibitory mEFF ratios (mEFF
= 1.6 with P < 0.0001) when compared to untreated con-
trol. Interestingly, blocking of beta1-integrin function by
treating cells with mAb13, showed a more effective inhi-
bition of mEFF ratios in tumor-associated (36% inhibi-
tion) than in control 3D ECMs (18% inhibition),
reaching 1.4 mEFF ratios with statistical P values smaller
than 0.0001 in both cases. On the other hand, 50 nM
Wortmannin and mAb13 showed no significant differ-
ences (mEFF = 1.4 with P = 0.2022) when compared to
each other in control 3D ECMs. The effects of these treat-
ments were modest (mEFF = 1.6 and 1.4, respectively) yet
still significantly different from each other (P = 0.0005) in
tumor-associated 3D ECMs. Since the most effective mEFF
inhibitory effects were attained when both PI3K and
beta1-integrin were blocked simultaneously, results sug-
gested that both pathways played a role in regulating 3D
matrix induced cell morphologies. However, results also
suggested that while beta1-integrin more effectively regu-
lated tumor-associated 3D matrix induced MDA-MB-231
spindled morphologies, control 3D matrix-induced mor-
phology seemed to be more sensitive to PI3K inhibition.
PI3K and beta1-integrin differentially regulate staged 3D 
matrix induced velocity, directionality and relative track 
orientation in MDA-MB-231 cells
Next, we decided to analyze the staged 3D matrix induced
invasive characteristics of MDA-MB-231 cells while ques-
tioning the roles that PI3K and beta1-integrin play in
these invasive behaviors. Three different aspects of staged
3D matrix induced single cell invasion, velocity, direction-
ality and relative track orientation, were measured in
response to the presence or absence of PI3K and beta1-
integrin inhibitors (Wortmannin and/or mAb13, respec-
tively). For this, six-hour time-lapse videos were created in
a semi-high throughput manner thus simultaneously
recording the cell's motile behaviors in response to the
various experimental settings (see Methods). Additional
files 4, 5 and 6 (Movies 4, 5 and 6) contain a representa-
tive example for each condition tested.
Velocity
Cell velocities were calculated as microns per hour. As
shown in Figure 4 and summarized in Tables 3 and 4, the
velocity of cell displacement was significantly slower in
2D when compared to staged control and tumor-associ-
ated 3D ECMs (12 μm/h vs. 23 μm/h and 19 μm/h,
respectively with Ps < 0.0001). In addition, the relatively
high velocities observed in both control and tumor-asso-
ciated 3D ECMs were not significantly different from each
other (P = 0.1606). Measurements under PI3K blockage
showed that while 10 nM Wortmannin effectively inhib-
ited cell velocity in 3D control, this concentration had no
effect in tumor-associated 3D ECMs (17 μm/h and 19 μm/
h with P = 0.0023 and 0.5286, respectively). Higher Wort-
mannin concentrations (50 nM) slightly, yet not signifi-
cantly, further inhibited cell velocities induced by 3D
control, while this concentration caused a statistically sig-
nificant inhibition of velocity induced by tumor-associ-
ated 3D ECMs (15 vs. 16 μm/h with P = 0.2859 vs. 0.0114,
respectively). Interestingly, mAb13 treatments, blocking
the function of beta1-integrins, were found to have greater
effects in control than in tumor-associated 3D ECMs (9
μm/h vs. 14 μm/h representing 60% vs. 26% inhibition
compared to untreated, respectively). When both drugs
were used in combination, cells in control 3D ECMs were
significantly faster compared to mAb13 alone (12 μm/h
and 11 μm/h with P = 0.0348 and 0.0015, respectively).
In comparison, in tumor-associated matrices no addi-
tional effects were observed (14 μm/h and 13 μm/h with
P = 0.8733 and 0.1978, respectively). The results sug-
gested that beta1-integrin regulates the velocity of MDA-
MB-231 cells, and that PI3K inhibition somewhat abol-
ished the beta1-integrin regulatory effect in control 3D
ECMs, while these two pathways seemed to work in tan-
dem in the regulation of cell velocity induced by tumor-
associated 3D ECMs.
Table 1: 3D matrix induced morphology measurements; EFF ±
substrate 2D control 3D tumor-associated 3D
treatment Ctrl Ctrl Wt 10 
nM
Wt 50 
nM
mAb13 mAb13 
+Wt 10 
nM
mAb13 
+Wt 50 
nM
Ctrl Wt 10 
nM
Wt 50 
nM
mAb13 mAb13 
+Wt 10 
nM
mAb13 
+Wt 50 
nM
Median 
(mEFF)
1.5 1.7 1.5 1.4 1.4 1.3 1.3 2.2 2.3 1.6 1.4 1.4 1.3
Sample 
Size
172 251 192 294 173 130 221 292 210 290 206 181 248
Std. Err 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0
±EFF = elliptical form factor ratio.BMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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Directionality
Since we have previously shown that fibroblasts invade in
a directional manner within control 3D ECMs as opposed
to migrating randomly on 2D substrates [43], and in addi-
tion, directionality has been observed in vivo in highly
metastatic mammary cells invading through mesenchy-
mal stroma [25], directionality of cells was measured in
staged, control vs. tumor-associated, 3D ECMs. Cell direc-
tionality, was assessed by measuring the angle of direction
of each cell in segments spanning 10 minutes each. The
percentages of cell-directions including angles within 5°
from the mode angle, in each cell trajectory, were calcu-
lated and are shown in Figure 5 while a summary of the
data is presented in Tables 5 and 6. Cells with higher per-
centage of similar angles represent persistent directional
behaviors, while lower percentages indicate tracks that
followed random directions. Results indicated that while
cells moved randomly on 2D conditions (18%) they
seemed to invade with a high degree of directionality
through both control and tumor-associated 3D ECMs
(22% and 26%). Moreover, this increase in directionality
was significant between staged 3D matrices (P = 0.0109).
Measurements performed under inhibitory PI3K condi-
tions showed that while directionality was modestly to
significantly decreased by 10 and 50 nM Wortmannin in
control 3D matrices (19% and 18% with P = 0.0219 and
< 0.0001, respectively), the inhibitor seemed to have no
effect on directionality induced by tumor-associated 3D
ECMs (26% and 25% with P = 0.6641 and 0.5551, respec-
tively). On the other hand, while mAb13 seemed to have
no significant effect on cellular directionality in the con-
trol (19% with P = 0.2395), it appeared to have a pro-
found inhibitory effect in tumor-associated 3D ECMs
(18% with P < 0.0001). Combinations of Wortmannin
and mAb13 did not change observations obtained using
mAb13 as a single treatment. Results suggested that beta1-
integrin regulates tumor-associated 3D ECM-induced
directional invasion of MDA-MB-231 cells, while PI3K
somewhat regulated the directionality of these cells
induced by control 3D ECMs.
Relative track orientation
We have previously shown that similar to their in vivo
counterparts, tumor-associated ECMs present parallel
fiber patterns of organization [44]. In addition, it has been
suggested that cells utilize matrix-patterned fibers for their
mesenchymal type of invasive behavior [15,25,26]. There-
fore, we proceeded to measure the relative track orienta-
tions of cells in all conditions. For this, the mode angle of
cell-track orientation was calculated on each recorded
region, and all cell tracks in this region were reoriented to
fit a common arbitrary mode angle of 0°. Percentages of
cell-tracks sharing common angles were plotted (Figure
6). Conditions inducing 70% or more counts at 20° dis-
tance from the mode angle were considered as "organ-
ized." The results show a high degree of orientation in
cells invading through tumor-associated as opposed to
control 3D matrices (79% vs. 55%, respectively). In addi-
tion, low or high levels of PI3K inhibition did not appar-
ently affect the relative orientation of MDA-MB-231 cells
Table 2: morphology P values
Sample 2D 3D Wt 10 nM Wt 50 nM mAb13 mAb13 +Wt 10 nM mAb13 Wt 50 nM
untreated
Ctrl < 0.0001*** - 0.0016** < 0.0001*** < 0.0001*** < 0.0001*** < 0.0001***
TA < 0.0001*** < 0.0001*** 0.5975 < 0.0001*** < 0.0001*** < 0.0001*** < 0.0001***
Wt 10 nM
Ctrl - - - 0.1902 0.0221** 0.0009*** < 0.0001***
TA - - - < 0.0001*** < 0.0001*** < 0.0001*** < 0.0001***
Wt 50 nM
Ctrl - - - - 0.2022 0.0042** < 0.0001***
TA - - - - 0.0005*** < 0.0001*** < 0.0001***
mAb13
Ctrl - - - - - 0.1687 0.0005***
TA - - - - - 0.4596 0.0108*
mAb13 + Wt 10 nM
Ctrl - - - - - - 0.0686
TA - - - - - - 0.0742
P values were obtained using Mann-Whitney test. Non-significant values are underlined while relative significance levels are designated as 
extremely***, very**, or significant*. Bolded data represent conditions in which differences were observed between control and tumor-associated 
3D matrix induced EFF due to stated treatments.BMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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PI3K and beta1-integrin differently regulate staged 3D ECM induced MDA-MB-231 morphologies Figure 3
PI3K and beta1-integrin differently regulate staged 3D ECM induced MDA-MB-231 morphologies. MDA-MB-231 
cells were cultured overnight on 2D or within staged 3D ECMs, control and tumor-associated matrices, in the presence and/or 
absence of 10 and 50 nM Wortmannin and/or 50 μg/ml mAb13. a. Individually scattered dots represent elliptical form factors 
(EFF). Upper and lower borders of diamond shapes show 75 and 25 percentile EFF populations, respectively while diamond 
widths marked with a horizontal line denote median EFF values. b. Representative transmitted light micrographs depicting one 
cell for each stated experimental condition. Scale bar indicates 50 μm. Note that median EFF increases in response to tumor-
associated 3D ECMs, and that these EFFs can be inhibited by high Wortmannin or mAb13 treatments while combinations of 
both inhibitors seemed to inhibit better than each of these alone. See Table 1 for detailed quantitative data, Table 2 for statis-
tical information and Additional Files 4, 5 and 6 (Movies 4–6) for additional examples.BMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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invading through tumor-associated 3D ECMs (74% and
71%, respectively), while beta1-integrin inhibition effec-
tively disorganized their relative orientation reaching only
40% of tracks at 20° variance from the mode. Moreover,
the relative disorganized pattern seemed to prevail when
mAb13 was used in combination with low or high con-
centrations of Wortmannin (49% or 48%, respectively).
As expected, none of the treatments induced relative track
orientation in control 3D ECM induced MDA-MB-231
invasion. The results presented herein suggested that
tumor-associated, but not control 3D ECMs, induced an
oriented parallel pattern of invasion in MDA-MB-231,
and that this orientation is beta1-integrin dependent and
PI3K independent.
Discussion
It is well established that tumor-associated stromal ECMs
influence tumorigenesis [60]. It has been shown that
increase in collagen density, as seen in our late 3D matri-
ces [44], supports tumor formation, invasion and metas-
tases [61]. Moreover, it has been proposed that Activated
Stromal Indexes, calculated as ratios between the degree
of fibrous mesenchymal collagen and levels of a desmo-
plastic marker (alpha-smooth muscle actin), can be useful
tools for assessing probable neoplastic prognostics [62].
In this study, we observed that assorted cells present dif-
ferent behaviors within reciprocal ECMs. Therefore, the
results of this study suggest a need for cellular predisposi-
tion to invasion even though classic 2D culturing meth-
ods were found to be insufficient for predicting
Table 3: matrix induced velocity (μm/h)
substrate 2D control 3D tumor-associated 3D
treatment Ctrl Ctrl Wt 10 
nM
Wt 50 
nM
mAb13 mAb13 
+Wt 10 
nM
mAb13 
+Wt 50 
nM
Ctrl Wt 10 
nM
Wt 50 
nM
mAb13 mAb13 
+Wt 10 
nM
mAb13 
+Wt 50 
nM
Mean 12 23 17 15 9 12 11 19 19 16 14 14 13
Sample 
Size
69 83 56 130 68 69 148 130 74 129 115 99 150
Std. Err 1 2 2 1 1 1 0 11 1 1 1 1
Table 4: velocity P values
Sample 2D 3D Wt 10 nM Wt 50 nM mAb13 mAb13 +Wt 10 nM mAb13 Wt 50 nM
untreated
Ctrl < 0.0001*** - 0.0023** < 0.0001*** < 0.0001*** < 0.0001*** < 0.0001***
TA < 0.0001*** 0.1606 0.5286 0.0003*** < 0.0001*** < 0.0001*** < 0.0001***
Wt 10 nM
Ctrl - - - 0.2859 < 0.0001*** 0.0190* 0.0193*
TA - - - 0.0114* < 0.0001*** < 0.0001*** < 0.0001***
Wt 50 nM
Ctrl - - - - 0.0002*** 0.1075 0.1571
TA - - - - 0.0304* 0.0247* 0.0002***
mAb13
Ctrl - - - - - 0.0348* 0.0015**
TA - - - - - 0.8733 0.1978
mAb13 + Wt 10 nM
Ctrl - - - - - - 0.4986
TA - - - - - - 0.2165
P values were obtained using Mann-Whitney test. Non-significant values are underlined while relative significance levels are designated as 
extremely***, very**, or significant*. Bolded data represent conditions in which differences were observed between control and tumor-associated 
3D matrix induced velocity due to stated treatments.BMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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tumorigenicity of cells. This is particularly apparent when
comparing 3D to 2D conditions. For example, in 2D con-
ditions, the invasive potential of MCF-10A, MCF-7 and
MDA-MB-231 cells could not be determined as they
exhibited similar behaviors. Nevertheless, it was not sur-
prising to discover that the stage of the 3D matrices further
contributed to the induction of in vivo-like cell invasion.
It has previously been shown that matrix extracts obtained
from murine mammary glands at various developmental
stages, differently influence MDA-MB-231 invasion [63],
and that both age and reproductive state of stroma, can
differentially affect breast tumor development [64]. In
addition, it has been established that diverse pathways
affect distinct cell invasion strategies, such as "mesenchy-
Staged 3D ECMs induce relatively fast MDA-MB-231 invasion that is differentially regulated by PI3K and beta1-integrinpathways Figure 4
Staged 3D ECMs induce relatively fast MDA-MB-231 invasion that is differentially regulated by PI3K and beta1-
integrinpathways. Time-lapse assays spanning 6 h were carried out as described in Methods, to determine the velocity of 
MDA-MB-231 cells cultured on 2D or within staged 3D ECMS in the presence and/or absence of 10 and 50 nM Wortmannin 
and/or 50 μg/ml mAb13. Cell velocities, calculated in microns per hour (μm/h), were plotted as individual dots while mean 
velocities are marked with horizontal lines (see Tables 3 and 4 for quantitative details). Note that Wortmannin and mAb13 
treatments induced different effects in velocities of cells invading through control vs. tumor-associated 3D ECMs.BMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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mal invasion," characterized by spindled cells that invade
following the direction of ECM fibers, vs. "amoeboid
invasion," where rounded cells move between fibers in a
less directional or more random manner [27,54,65].
Interestingly, tampering with mesenchymal invasion
causes changes to invasive strategy (mesenchymal to
amoeboid), yet fails to block invasion in vivo [25,26,66].
Knowing that MDA-MB-231 cells have undergone epithe-
lial-to-mesenchymal transition [55], we questioned
whether early or late stromal stages (e.g., control and
tumor-associated 3D ECMs), could differentially regulate
MDA-MB-231's behavior. What is more, it has been sug-
gested that beta1-integrin dependent, yet PI3K independ-
ent pathways, could regulate ECM-induced Akt/PKB
activity [67]. Therefore, we tested if interfering with path-
ways known to regulate cell invasion in general (e.g., Akt/
PKB) or mesenchymal type of invasion in particular
(beta1-integrin), would differentially affect the cells
invading through early vs. late stromal ECMs. Figure 7
summarizes our results depicting all the cell trajectory
tracks obtained for each condition tested (for representa-
tive videos see Additional files 4, 5 and 6; Movies 4–6).
The relative spread of the star-like graphs in this figure,
depicts the cell velocities where bigger stars represent fast
cell movements. By looking at the patterns of the tracks, it
is evident that conditions sustaining directional move-
ments presented relatively straight line-tracks while wiggle
lines represented directions that are more random. In
regards to relative track orientations, the agglomeration of
tracks near the X-axis shows the degree of tracks that were
found to orient towards the most common angle on each
experimental condition. Therefore, as a synopsis, we
Table 5: 3D matrix induced directionality (±%)
substrate 2D control 3D tumor-associated 3D
treatment Ctrl Ctrl Wt 10 
nM
Wt 50 
nM
mAb13 mAb13 
+Wt 10 
nM
mAb13 
+Wt 50 
nM
Ctrl Wt 10 
nM
Wt 50 
nM
mAb13 mAb13 
+Wt 10 
nM
mAb13 
+Wt 50 
nM
Mean 18 22 19 18 19 20 19 26 26 25 18 19 18
Sample 
Size
69 83 56 130 68 69 148 130 74 129 115 99 150
Std. Err 1 1 1 1 1 1 0 11 1 1 1 0
±% of cells at 5° distance from mode angle
Table 6: directionality P values
Sample 2D 3D Ctrl Wt 10 nM Wt 50 nM mAb13 mAb13 + Wt 10 nM mAb13 Wt 50 nM
untreated
Ctrl < 0.0014** - 0.0219* < 0.0001*** 0.2395 0.6252 0.0377*
TA < 0.0001*** 0.0109* 0.6641 0.5551 < 0.0001*** < 0.0001*** < 0.0001***
Wt 10 nM
Ctrl - - - 0.3691 0.0545 0.0109* 0.1144
TA - - - 0.3983 < 0.0001*** < 0.0001*** < 0.0001***
Wt 50 nM
Ctrl - - - - 0.0002*** < 0.0001*** 0.0004***
TA - - - - < 0.0001*** < 0.0001*** < 0.0001***
mAb13
Ctrl - - - - - 0.2808 0.5132
TA - - - - - 0.4318 0.2500
mAb13 + Wt 10 nM
Ctrl - - - - - - 0.0568
TA - - - - - - 0.8769
P values were obtained using Mann-Whitney test. Non-significant values are underlined while relative significance levels are designated as 
extremely***, very**, or significant*. Bolded data represent conditions in which differences were observed between control and tumor-associated 
3D matrix induced directionality due to stated treatments.BMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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observed that indeed both early (control) and late
(tumor-associated) 3D ECMs support a mesenchymal
type of invasive behavior in MDA-MB-231 cells by induc-
ing beta1-integrin regulated spindled morphology (Figure
3) and a relatively fast (Figure 4) and directional migra-
tion (Figure 5). Inhibition of beta-1 integrin effectively
blocked the mesenchymal type of invasion supported by
early matrix. Nevertheless, in late matrices, beta-1 integrin
inhibition prompted little effect in velocity, while cellular
morphology, directionality, and relative track organiza-
tion of the trajectories were greatly influenced. This data
suggests that, in the late-stage matrix, beta-1 integrin inhi-
bition induces a change of invasive strategy. As a result, we
believe that it is possible that tumor-associated (late), but
not control (early), 3D ECMs support alternative, other
than mesenchymal type of MDA-MB-231, invasion.
Whether this altered invasive behavior is "amoeboid-
like," is out of the scope of this work yet, the fact that the
invasive behavior is random (as opposed to directional)
and the cells present active blebs only in late 3D matrices
under beta1-integrin inhibition (compare Additional file
4 and 5 (Movies 4 and 5)), strongly support this idea. We
Tumor-associated 3D ECMs induce directional MDA-MB-231 invasion regulated by beta1-integrin but not PI3K Figure 5
Tumor-associated 3D ECMs induce directional MDA-MB-231 invasion regulated by beta1-integrin but not 
PI3K. Time-lapse assays were carried out to determine the directionality of MDA-MB-231 cells in the presence and/or 
absence of 10 and 50 nM Wortmannin and/or 50 μg/ml mAb13. Dots plotted in graph indicate percentages of angles positioned 
within 5° from the identified mode angle per cell (data was rounded and therefore appears organized (for additional details, see 
Material and Methods)). Upper and lower borders of diamond shapes show 75 and 25 percentile populations, respectively, 
while diamond widths marked with a horizontal line, mark median percentages at 5° variance from the mode angle direction. 
Note that when compared with 2D and 3D matrices, tumor-associated 3D matrices induced greater degree of directionality, 
which was regulated by beta1-integrin but not by PI3K activity. See Tables 5 and 6 for statistical information.BMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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Tumor-associated 3D ECMs induce relative organized MDA-MB-231 track orientations regulated by beta1-integrin but not by  PI3K pathways Figure 6
Tumor-associated 3D ECMs induce relative organized MDA-MB-231 track orientations regulated by beta1-
integrin but not by PI3K pathways. Time-lapse assays were carried out using MDA-MB-231 cells cultured on 2D or within 
staged 3D ECMs in the presence and/or absence of 10 and 50 nM Wortmannin and/or 50 μg/ml mAb13. Representative trajec-
tory tracks were attained using Microsoft Excel as described in Methods. Orientation angles of the trajectories relative to the 
X-axis were rounded to the nearest 20th degree in order to identify a mode orientation angle. This mode angle was arbitrarily 
set as 0° and the original angles were rotated accordingly. Next, a new rounding of the rotated but otherwise intact data was 
performed only this time it was approximated to the 10th degree (see Methods for additional details). The percentages of 
angles positioned within 20° variance from the mode angle are indicated in the figure. Note that tumor-associated 3D matrices 
support oriented cell invasive trajectories (greater than 70% organization) in a beta1-integrin but not PI3K dependent manner.BMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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PI3K and beta1-integrin pathways play different roles in regulating 3D matrix-induced breast cancer cell invasion Figure 7
PI3K and beta1-integrin pathways play different roles in regulating 3D matrix-induced breast cancer cell inva-
sion. Representative MDA-MB-231 trajectory tracks were attained as described in Methods. Orientation angles of the trajec-
tories relative to the X-axis were rounded to the nearest 20th degree in order to identify a mode orientation angle. This mode 
was arbitrarily set as 0° and the original angles were rotated accordingly (see Methods for additional details). The resulting 
tracks were plotted as if all shared a common origin to generate a star like pattern. Graph scales are shown in micrometers to 
appreciate distances travelled during the recorded 6 h periods. Note that cells invading through tumor-associated 3D ECMs 
appear to move relatively fast (length of tacks), directional (straightness of tracks) and with a relative greater level of common 
or parallel orientation (orientation of tracks near the X-axis) when compared to control 3D ECMs. In addition, inhibition of 
beta1-integrin function (mAb13) effectively blocked cell invasion through control 3D ECMs, as shown by the resulting relatively 
small star. In contrast, blockage of beta1-integrin activity in these invasive cells triggered a change in the invasive strategy 
induced by tumor-associated 3D ECMs. This observation is apparent by contemplating the relatively large stars with wiggle 
tracks, as opposed to straight tracks, that lack organization near the X-axis in all experimental data attained in the presence of 
mAb13.BMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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observed that beta1-integrin and/or PI3K pathways differ-
entially regulate early vs. late stromal matrix induced (in
vivo-like) invasive behavior. Furthermore, this work sup-
ports the notion that cells can behave differently within
early vs. late stromal ECMs, and that both "cells" and
"matrices" need predisposition to attain favorable inva-
sion. For example, inhibition of PI3K or, to a better extent,
blocking beta1-integrin function could potentially reduce
invasive cell velocities in early (control) 3D matrices, yet
combinations of these drugs would be counteractive. On
the other hand, in late stage stromal matrices (tumor-
associated), this combinatorial approach inhibits veloci-
ties to the same extent as beta1-integrin blockage alone.
Perhaps, beta1-integrin inhibition in combination with
that of additional pathways will prove to be more effective
in the future for inhibition of possible alternative invasive
strategies.
Conclusion
Our data suggests that while both early and later matrices
sustain mesenchymal invasion of MDA-MB-231 cells,
only late stromal 3D matrices support a change of invasive
strategy triggered by beta1-integrin inhibition. Therefore,
our observations imply that "staging" stromal matrices,
analogously to clinically relevant "tumor staging," might
be an important step in assertively selecting invasive drug
inhibitors. In addition, this work presents novel matrix-
based assays to score tumor cell invasiveness and stroma
permissiveness. These assays can be performed in a rela-
tively short period of time, so that the stage of matrices
produced  in vitro accurately mimic the in vivo tumor
microenvironment of the patient. It is possible that future
applications of these assays could be used to score the
effectiveness of targeted cancer drugs in inhibiting differ-
ent aspects of cancer cell metastasis. Hence, this study
could one day facilitate the identification of individuals at
increased risk of recurrence, which remains a considerable
challenge in the field [68], as well as personalized effective
treatments.
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Additional material
Additional file 1
Normal cell motility through staged 3D ECMs. Montage of six hour 
time-lapse videos depicting MCF-10A cells moving through control (top 
left) and tumor-associated (top right) 3D ECMs or on 2D (bottom left).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-9-94-S1.mov]
Additional file 2
Tumorigenic cell motility through staged 3D ECMs. Montage of six 
hour time-lapse videos depicting MCF-7 cells moving through control (top 
left) and tumor-associated (top right) 3D ECMs or on 2D (bottom left).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-9-94-S2.mov]
Additional file 3
Invasive cell motility through staged 3D ECMs. Montage of six hour 
time-lapse videos depicting MDA-MB-231 cells moving through control 
(top left) and tumor-associated (top right) 3D ECMs or on 2D (bottom 
left).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-9-94-S3.mov]
Additional file 4
Invasive cell motility through control 3D ECMs under PI3K and/or 
beta-1 integrin inhibition. Montage of six hour time-lapse videos depict-
ing MDA-MB-231 cells invading through control 3D ECMs (top left) in 
the presence of 10 nM Wortmannin (top right), 50 μg/ml mAb13 (bot-
tom left) or a combination of both mAb13 and 10 nM Wortmannin (bot-
tom right).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-9-94-S4.mov]BMC Cancer 2009, 9:94 http://www.biomedcentral.com/1471-2407/9/94
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